News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cubist Pharmaceuticals, Inc. (CBST) Enrolls 1st Patient in Phase 3 CB-5945 Program for the Treatment of Opioid-Induced Constipation


10/31/2012 7:32:08 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the initiation of the Phase 3 CB-5945 opioid-induced constipation (OIC) Ascent program with the enrollment of the first patient in the long-term safety study, which is one of four registrational studies in patients with chronic non-cancer pain.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES